Decoding Pfizer's Options Activity: What's the Big Picture?

Financial giants have made a conspicuous bullish move on Pfizer. Our analysis of options history for Pfizer PFE revealed 11 unusual trades.

Delving into the details, we found 63% of traders were bullish, while 36% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $103,317, and 8 were calls, valued at $762,790.

Projected Price Targets

Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $15.0 to $32.5 for Pfizer during the past quarter.

Analyzing Volume & Open Interest

Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.

This data can help you track the liquidity and interest for Pfizer's options for a given strike price.

Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Pfizer's whale activity within a strike price range from $15.0 to $32.5 in the last 30 days.

Pfizer Option Activity Analysis: Last 30 Days

Significant Options Trades Detected:

About Pfizer

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.

In light of the recent options history for Pfizer, it's now appropriate to focus on the company itself. We aim to explore its current performance.

Pfizer's Current Market Status

• Trading volume stands at 5,245,548, with PFE's price down by -0.1%, positioned at $29.37.
• RSI indicators show the stock to be may be approaching overbought.
• Earnings announcement expected in 20 days.

Expert Opinions on Pfizer

5 market experts have recently issued ratings for this stock, with a consensus target price of $33.6.

• An analyst from Barclays persists with their Equal-Weight rating on Pfizer, maintaining a target price of $28.
• Maintaining their stance, an analyst from Truist Securities continues to hold a Buy rating for Pfizer, targeting a price of $36.
• An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $45.
• In a cautious move, an analyst from TD Cowen downgraded its rating to Market Perform, setting a price target of $32.
• An analyst from UBS has decided to maintain their Neutral rating on Pfizer, which currently sits at a price target of $27.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Pfizer options trades with real-time alerts from Benzinga Pro.